On this blog, we have been following two Celltrion biosimilars: CT-P10 (rituximab) and CT-P13 (infliximab, the subject of the Janssen v. Celltrion litigation). According to a Celltrion press release, new data released today at the 2016 American College of Rheumatology (ACR) Annual Meeting show that the efficacy and safety profile…